Proprietary AI analyst is now available

Nanjing Medlander Medical Valuation Multiples

Discover Nanjing Medlander Medical's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Sunmax Biotechnology, Yidu Tech, Synektik, Oculis Holding and more.

Nanjing Medlander Medical Overview

About Nanjing Medlander Medical

Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.


Founded

2013

HQ

China

Employees

582

Financials (FY)

Revenue: $64M
EBITDA: $20M

EV

$542M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Nanjing Medlander Medical Financials

Nanjing Medlander Medical reported last fiscal year revenue of $64M and EBITDA of $20M.

In the same fiscal year, Nanjing Medlander Medical generated $45M in gross profit, $20M in EBITDA, and $15M in net income.


Nanjing Medlander Medical P&L

In the most recent fiscal year, Nanjing Medlander Medical reported revenue of $64M and EBITDA of $20M.

Nanjing Medlander Medical is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 32%, and net margin of 24%.

See analyst estimates for Nanjing Medlander Medical
Last FY202320242025202620272028
Revenue$64M$50M$63M$64M
Gross Profit$45M$36M$45M$45M
Gross Margin70%71%72%70%
EBITDA$20M$18M$23M$20M
EBITDA Margin32%35%36%32%
EBIT Margin24%22%27%24%
Net Profit$15M$13M$15M$15M
Net Margin24%26%24%24%

Financial data powered by Morningstar, Inc.

Nanjing Medlander Medical Stock Performance

Nanjing Medlander Medical has current market cap of $653M, and enterprise value of $542M.


Nanjing Medlander Medical's stock price is $6.53.

Nanjing Medlander Medical has an EPS (earnings per share) of $0.15.

See more trading valuation data for Nanjing Medlander Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$542M$653M0.7%---$0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Nanjing Medlander Medical Valuation Multiples

Nanjing Medlander Medical trades at 8.5x EV/Revenue multiple, and 26.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Nanjing Medlander Medical

Nanjing Medlander Medical Financial Valuation Multiples

As of June 10, 2026, Nanjing Medlander Medical has market cap of $653M and EV of $542M.

Nanjing Medlander Medical has a P/E ratio of 43.0x.

Last FY202320242025202620272028
EV/Revenue8.5x10.8x8.6x8.5x
EV/EBITDA26.7x30.6x24.0x26.7x
EV/EBIT36.0x49.2x32.6x36.0x
EV/Gross Profit12.1x15.1x12.0x12.1x
P/E43.0x49.2x43.5x43.0x
EV/FCFn/m59.4xn/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Nanjing Medlander Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Nanjing Medlander Medical Margins & Growth Rates

In the most recent fiscal year, Nanjing Medlander Medical reported gross margin of 70%, EBITDA margin of 32%, and net margin of 24%.

See estimated margins and future growth rates for Nanjing Medlander Medical

Nanjing Medlander Medical Margins

Last FY20242025202720282029
Gross Margin70%72%70%
EBITDA Margin32%36%32%
EBIT Margin24%27%24%
Net Margin24%24%24%
FCF Margin(3%)(2%)(3%)

Nanjing Medlander Medical Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth25%2%
Gross Profit Growth26%(1%)
EBITDA Growth28%(10%)
EBIT Growth51%(10%)
Net Profit Growth13%1%
FCF Growth(112%)77%

Data powered by FactSet, Inc. and Morningstar, Inc.

Nanjing Medlander Medical Operational KPIs

Nanjing Medlander Medical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Nanjing Medlander Medical
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.1M---
S&M Expenses to Revenue9%8%7%9%
G&A Expenses to Revenue5%6%5%5%
R&D Expenses to Revenue14%17%14%14%
Opex to Revenue47%49%45%47%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Nanjing Medlander Medical Competitors

Nanjing Medlander Medical competitors include Sunmax Biotechnology, Yidu Tech, Synektik, Oculis Holding, Beta Bionics, Advanced Medical Solutions Group, Equasens, Craneware, Bioventus and Lumibird.

Most Nanjing Medlander Medical public comparables operate across Medical Devices, Healthcare Software, BioTech, B2B SaaS, Vertical SaaS, HealthTech and FemTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sunmax Biotechnology9.8x-17.6x-
Yidu Tech3.3x-(26.0x)-
Synektik2.9x2.6x11.7x10.2x
Oculis Holding251.5x297.7x(3.6x)(3.7x)
Beta Bionics4.5x3.9x(8.4x)(6.9x)
Advanced Medical Solutions Group2.4x2.3x10.8x10.3x
Equasens2.4x2.3x7.9x8.2x
Craneware3.2x3.0x10.2x9.5x

This data is available for Pro users. Sign up to see all Nanjing Medlander Medical competitors and their valuation data.

Start Free Trial

Nanjing Medlander Medical VC Funding History

Before going public, Nanjing Medlander Medical raised $2M in total equity funding, across 2 rounds.


Nanjing Medlander Medical Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-19Series AGreenwoods Asset Management$1M--
Dec-18AngelCoastal Capital; Ju Shi Chuang Tou$400K--

Investments by Nanjing Medlander Medical

Nanjing Medlander Medical has invested in 1 company to date.

Latest investment by Nanjing Medlander Medical was on June 4th 2026. Nanjing Medlander Medical invested in Zhimei Keji in their $30M Undisclosed stage round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Nanjing Medlander Medical

Zhimei Keji
Description
Zhimei Keji is an e-commerce provider specializing in beauty products such as trendy makeup, facial skincare, makeup tools, bundled sets, body care items, beauty equipment, perfumes, and cleansing products. The company operates via gimay.net to serve consumer markets.
HQ CountryChina
HQ City
Shantou
Deal Date4 Jun 2026
RoundUndisclosed stage
Raised$30M
InvestorsBeijing Guoshi Zhida Private Equity Fund Management; Nanjing Medlander Medical
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Nanjing Medlander Medical investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Nanjing Medlander Medical

When was Nanjing Medlander Medical founded?Nanjing Medlander Medical was founded in 2013.
Where is Nanjing Medlander Medical headquartered?Nanjing Medlander Medical is headquartered in China.
How many employees does Nanjing Medlander Medical have?As of today, Nanjing Medlander Medical has over 582 employees.
Is Nanjing Medlander Medical publicly listed?Yes, Nanjing Medlander Medical is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Nanjing Medlander Medical?Nanjing Medlander Medical trades under 688273 ticker.
When did Nanjing Medlander Medical go public?Nanjing Medlander Medical went public in 2022.
Who are competitors of Nanjing Medlander Medical?Nanjing Medlander Medical main competitors include Sunmax Biotechnology, Yidu Tech, Synektik, Oculis Holding, Beta Bionics, Advanced Medical Solutions Group, Equasens, Craneware, Bioventus, Lumibird.
What is the current market cap of Nanjing Medlander Medical?Nanjing Medlander Medical's current market cap is $653M.
What is the current revenue of Nanjing Medlander Medical?Nanjing Medlander Medical's last fiscal year revenue is $64M.
What is the current EV/Revenue multiple of Nanjing Medlander Medical?Current revenue multiple of Nanjing Medlander Medical is 8.5x.
Is Nanjing Medlander Medical profitable?No, Nanjing Medlander Medical is not profitable.
How many companies Nanjing Medlander Medical has acquired to date?Nanjing Medlander Medical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Nanjing Medlander Medical has invested to date?As of June 2026, Nanjing Medlander Medical has invested in 1 company.
What was the last Nanjing Medlander Medical investment?On 4th June 2026 Nanjing Medlander Medical invested in Zhimei Keji, participating in a $30M Undisclosed stage round, alongside Beijing Guoshi Zhida Private Equity Fund Management.
In what companies Nanjing Medlander Medical invested in?Nanjing Medlander Medical invested in Zhimei Keji.

See public comps similar to Nanjing Medlander Medical

Lists including Nanjing Medlander Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial